The regulatory role of Valpha14 NKT cells in innate and acquired immune response, Annu Rev Immunol, vol.21, pp.483-513, 2003. ,
The biology of NKT cells, Annu Rev Immunol, vol.25, pp.297-336, 2007. ,
Presumed guilty: natural killer T cell defects and human disease, Nat Rev Immunol, vol.11, pp.131-173, 2011. ,
Recognition of CD1d-restricted antigens by natural killer T cells, Nat Rev Immunol, vol.12, pp.845-57, 2012. ,
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions, Nat Rev Immunol, vol.13, pp.101-118, 2013. ,
Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans, Clin Immunol, vol.140, pp.119-148, 2011. ,
NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells, J Immunol, vol.171, pp.5140-5147, 2003. ,
NKT cells as an ideal anti-tumor immunotherapeutic, Front Immunol, vol.4, p.409, 2013. ,
Harnessing invariant NKT cells in vaccination strategies, Nat Rev Immunol, vol.9, pp.28-38, 2009. ,
NKT cell adjuvants in therapeutic vaccines against hematological cancers, Oncoimmunology, vol.2, p.22615, 2013. ,
KRN7000, a novel immunomodulator, and its antitumor activities, Oncol Res, vol.7, pp.529-563, 1995. ,
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides, Science, vol.278, pp.1626-1635, 1997. ,
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents, Clin Transl Immunology, vol.5, p.69, 2016. ,
Glycolipid activators of invariant NKT cells as vaccine adjuvants, Immunogenetics, vol.68, pp.597-610, 2016. ,
Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells, Med Res Rev, vol.34, pp.45-76, 2014. ,
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant, Proc Natl Acad Sci U S A, vol.107, pp.13010-13015, 2010. ,
, Frontiers in Immunology | www.frontiersin.org, vol.8, p.879, 2017.
Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity, Blood, vol.113, pp.4262-72, 2009. ,
Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction, J Immunol, vol.190, pp.5609-5628, 2013. ,
Immunotherapy with artificial adjuvant vector cells: harnessing both arms of the immune response, Oncoimmunology, issue.2, p.23432, 2013. ,
Systemic DC activation modulates the tumor microenvironment and shapes the longlived tumor-specific memory mediated by CD8+ T cells, Cancer Res, vol.76, pp.3756-66, 2016. ,
Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells, Cancer Res, vol.73, pp.62-73, 2013. ,
Cross-presentation of glycolipid from tumor cells loaded with alphagalactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells, J Exp Med, vol.204, pp.2641-53, 2007. ,
Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice, J Immunol, vol.178, pp.2853-61, 2007. ,
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity, Blood, vol.110, pp.2013-2022, 2007. ,
Hung C-F. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors, Vaccine, vol.26, pp.5855-63, 2008. ,
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma, Blood, vol.120, pp.3019-3048, 2012. ,
Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma, Clin Cancer Res, vol.18, pp.6446-59, 2012. ,
Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells, Immunol Cell Biol, vol.91, pp.105-119, 2013. ,
Tumor cells loaded with ?-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma, Immunol Lett, vol.156, pp.132-141, 2013. ,
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines, Oncoimmunology, issue.2, p.23789, 2013. ,
An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment, Blood, vol.124, pp.2953-63, 2014. ,
Co-operation of ?-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model, Biochem J, vol.473, pp.7-19, 2016. ,
Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells, J Immunol, vol.178, pp.2721-2730, 2007. ,
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model, Cancer Res, vol.67, pp.7477-86, 2007. ,
Multiple antigen-targeted immunotherapy with alphagalactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells, J Immunother, vol.32, pp.219-250, 2009. ,
Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells, Cancer Sci, vol.96, pp.889-96, 2005. ,
Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression, J Immunol, vol.188, pp.4297-304, 2012. ,
Application of polymeric nanoparticles in immunotherapy, Curr Opin Allergy Clin Immunol, vol.12, pp.658-64, 2012. ,
Applications of nanotechnology for immunology, Nat Rev Immunol, vol.13, pp.592-605, 2013. ,
Particle platforms for cancer immunotherapy, Int J Nanomedicine, vol.8, pp.1683-96, 2013. ,
Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro, J Control Release, vol.144, pp.118-144, 2010. ,
Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles, J Drug Target, vol.19, pp.281-92, 2011. ,
PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines, Adv Drug Deliv Rev, vol.57, pp.475-82, 2005. ,
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat Rev Immunol, vol.10, pp.787-96, 2010. ,
Nanoparticle-based vaccine delivery for cancer immunotherapy, Immune Netw, vol.13, p.177, 2013. ,
Nanoscale drug delivery systems and the blood-brain barrier, Int J Nanomedicine, vol.9, pp.795-811, 2014. ,
Design opportunities for actively targeted nanoparticle vaccines, Nanomedicine (Lond), vol.3, pp.343-55, 2008. ,
Nano/ micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives, J Control Release, vol.125, pp.193-209, 2008. ,
Current advances in research and clinical applications of PLGA-based nanotechnology, Expert Rev Mol Diagn, vol.9, pp.325-366, 2009. ,
Formulation and characterization of antigen-loaded PLGA nanoparticles for efficient cross-priming of the antigen, Immune Netw, vol.11, pp.163-171, 2011. ,
PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity, Hum Vaccin Immunother, vol.12, pp.1056-69, 2016. ,
CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes, Nat Immunol, vol.11, pp.303-315, 2010. ,
The location of splenic NKT cells favours their rapid activation by blood-borne antigen, EMBO J, vol.31, pp.2378-90, 2012. ,
Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy, Vaccine, vol.27, pp.3484-3492, 2009. ,
Activation of invariant Natural Killer T lymphocytes Frontiers in Immunology | www, vol.8, p.879, 2017. ,
, in response to the ?-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles, Int J Pharm, vol.423, pp.45-54, 2012.
The nanoparticulation by octaarginine-modified liposome improves ?-galactosylceramidemediated antitumor therapy via systemic administration, J Control Release, vol.171, pp.216-240, 2013. ,
Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes, Int Immunopharmacol, vol.15, pp.685-92, 2013. ,
Targeted delivery of lipid antigen to macrophages via the CD169/ sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation, Proc Natl Acad Sci U S A, vol.110, pp.7826-7857, 2013. ,
Targeted delivery of ?-galactosylceramide to CD8?+ dendritic cells optimizes type I NKT cell-based antitumor responses, J Immunol, vol.193, pp.961-970, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02436034
Virus-like particles and ?-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses, J Control Release, vol.159, pp.338-383, 2012. ,
Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses, Oncoimmunology, vol.5, p.1068493, 2015. ,
Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine, Int J Nanomedicine, vol.11, pp.6103-6124, 2016. ,
Synthetic TRP2 long-peptide and ?-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression, Vaccine, vol.33, pp.5838-5882, 2015. ,
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells, J Exp Med, vol.207, pp.1283-92, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00493468
Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells, J Exp Med, vol.207, pp.1273-81, 2010. ,
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells, J Exp Med, vol.207, pp.1261-71, 2010. ,
BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens, J Exp Med, vol.141, pp.1247-60, 2010. ,
A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens, Immunity, vol.40, pp.105-121, 2014. ,
Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs, Nat Immunol, vol.11, pp.313-333, 2010. ,
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin, J Clin Invest, vol.118, pp.2098-110, 2008. ,
Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas, Eur J Immunol, vol.44, pp.1947-55, 2014. ,
Harnessing human cross-presenting CLEC9A(+)XCR1(+) dendritic cells for immunotherapy, Front Immunol, vol.5, p.239, 2014. ,
Co-delivery of the NKT agonist ?-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses, Oncoimmunology ,
URL : https://hal.archives-ouvertes.fr/inserm-02436029
Therapeutic cancer vaccines: are we there yet?, Immunol Rev, vol.239, pp.27-44, 2011. ,
Increasing the efficacy of tumor cell vaccines by enhancing cross priming, Cancer Lett, vol.325, pp.155-64, 2012. ,
Dendritic-cell-based therapeutic cancer vaccines, Immunity, vol.39, pp.38-48, 2013. ,
Oncology meets immunology: the cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013. ,
Trial watch: peptide-based anticancer vaccines, Oncoimmunology, vol.4, p.974411, 2015. ,
Co-administration of ?-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells, Clin Immunol, vol.168, pp.6-15, 2016. ,